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Heno¨ch-Scho¨nlein purpura nephritis (HSPN) is considered a
systemic form of immunoglobulin A nephropathy (IgAN).
Although these are different pictures of a single disease,
there are no studies directly comparing long-term outcomes
of these two clinical entities. To clarify this, we studied 120
patients with biopsy-proven HSPN and 1070 patients with
IgAN. The primary outcome was the composite of a doubling
of baseline serum creatinine, end-stage renal disease, or
death. Secondary outcomes included the individual renal
outcomes or the rate of decline in estimated glomerular
filtration rate. In the unmatched cohort, patients with HSPN
had more vasculitic symptoms, more favorable histologic
features, and were more commonly treated with steroids
than patients with IgAN. The risk of reaching the primary
outcome was significantly lower in HSPN patients than
patients with IgAN (hazard ratio, 0.67). The 1:2 propensity
score matching gave matched pairs of 89 patients with HSPN
and 178 patients with IgAN, resulting in no differences in
baseline conditions. In this matched cohort, there were no
significant differences in reaching the primary and secondary
outcomes between the two groups. Thus, after adjustment
by propensity score matching, clinical outcomes did not
differ between HSPN and IgAN, suggesting the two forms of
the same disease have a similar prognosis.
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Heno¨ch-Scho¨nlein purpura nephritis (HSPN) is a small
vessel vasculitis that can affect not only the kidneys but also
the skin, gut, and joints, to varying degrees. In contrast,
immunoglobulin A nephropathy (IgAN) is known as a renal-
limited, nonsystemic disease.1 However, HSPN and IgAN
share many clinical, histological, and immunological fea-
tures.2–4 In particular, both are characterized by the presence
of mesangial IgA deposits, suggesting that both have a
common pathogenic mechanism. Nowadays, HSPN is
considered to be a systemic form of IgAN,2–4 and it has been
suggested that the two conditions are different manifestations
of a single disease process.5,6
Compared with the high incidence of IgAN among adult-
onset glomerular diseases, HSPN rarely occurs in adults.
Accordingly, there are considerably fewer reports investigat-
ing the renal outcomes of HSPN than investigating the renal
outcomes of IgAN. In addition, the sample sizes of the
studies are relatively small. In general, 15–20% of adult
patients with IgAN reach end-stage renal disease (ESRD)
within 10 years from apparent disease onset and up to
25–34% within 20 years.5,7 According to two large cohort
studies from Italy8 and France,9 the risk of developing ESRD
in adults with HSPN is 20–25% within 10 years after
diagnosis.5,8 However, 20–30% of these patients have
moderate-to-nephrotic range proteinuria, renal insuffi-
ciency, or both at the onset of disease,8,10,11 whereas most
patients with IgAN initially have asymptomatic urinary
abnormalities with normal renal function and minimal-to-
moderate proteinuria. In addition, systemic manifestations
of vasculitis are more common in patients with HSPN. Thus,
steroids or other immunosuppressive drugs are more
frequently prescribed to patients with HSPN than to those
with IgAN. These factors make it difficult to directly
compare clinical outcomes between the two clinical entities,
and whether HSPN and IgAN have a similar prognosis is
currently unknown. With this background in mind, we
conducted a multicenter, observational study and used
propensity score (PS) matching to compare long-term renal
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outcomes of adult HSPN patients with those of adult
patients with IgAN.
RESULTS
Baseline characteristics
A flow diagram describing the patient samples and exclusions
is shown in Figure 1. Baseline characteristics of the patients
who met the inclusion criteria are shown in Table 1. In the
unmatched cohort, patients with HSPN were significantly
younger than patients with IgAN (33.2 vs. 37.7 years of age,
P¼ 0.010). Prior history of hypertension was more common
in patients with HSPN than in patients with IgAN (25.0% vs.
13.3%, P¼ 0.004), but baseline systolic, diastolic, and mean
arterial pressure were not different between the two groups.
Extrarenal manifestations were common in patients with
HSPN, whereas these were not observed in patients with IgAN.
In addition, serum C-reactive protein levels were higher in
patients with HSPN than in patients with IgAN, supporting
evidence for vasculitic features in the former. Baseline serum
creatinine and estimated glomerular filtration rate (eGFR),
urinary protein-to-creatinine ratio (UPCR), and 24-h urinary
protein excretion were comparable between the two groups.
However, when patients were categorized according to eGFR,
145 (14.4%) patients with IgAN had eGFR o60 ml/min per
1.73 m2 compared with 7 (7.6%) patients with HSPN
(P¼ 0.073). Severe renal impairment, which was defined as
eGFR o30 ml/min per 1.73 m2, was observed in 13 (1.3%)
patients with IgAN, whereas there was no such patient with
HSPN. There were no differences in gender, diabetes, the
presence of gross hematuria, and laboratory parameters, such
as serum levels of total cholesterol, albumin, IgA, complement
(C3 and C4), and hepatitis B surface antigen positivity.
However, steroids were more frequently prescribed to patients
with HSPN than to patients with IgAN (40.2% vs. 14.2%,
P¼ 0.001). Other immunosuppressants such as cyclosporine
or cyclophosphamide were used in small number of patients
who did not respond to or tolerate steroids. All patients were
maintained on low-dose steroids while receiving other
immunosuppressants and total duration of steroids and/or
immunosuppressants did not differ between the two groups.
The unbalanced conditions at baseline between the two
groups were controlled by using PS matching. The 1:2 PS
matching yielded matched pairs of 89 patients with HSPN
and 178 patients with IgAN, resulting in no differences in
age, gender, comorbid diseases, such as hypertension and
diabetes mellitus, mean arterial pressure, laboratory biomar-
kers, pathologic findings, proportion of patients with renal
failure, and treatment modalities (Table 1).
Patient outcomes for the unmatched cohort
In the unmatched cohort, 18 patients (19.6%) with HSPN
reached a composite outcome compared with 398 patients
(39.4%) with IgAN (P¼ 0.047; Figure 2a). Among these
patients, 16 patients (17.4%) with HSPN reached a doubling
of the baseline serum creatinine concentration (D-SCr)
compared with 249 patients (24.6%) with IgAN, but it did
not reach statistical significance (P¼ 0.075; Figure 2b).
However, ESRD occurred in 13 patients (14.1%) with HSPN
and 222 patients (22.0%) with IgAN (P¼ 0.034; Figure 2c,
Table 2). Death occurred in two patients (2.2%) with HSPN
Biopsy-proven HSPN
(n =120)
Biopsy-proven IgAN
(n =1070)
Analyzed
(n =92)
1:2 PS
matching cohort
Matched (n =89)
Composite end point Composite end point
-Cr-doubling (n =18, 20.2%)
-ESRD (n =5, 5.6%)
-Death (n =2, 2.2%)
-Cr-doubling (n =36, 20.2%)
-ESRD (n =13, 7.3%)
-Death (n =2, 1.1%)
Matched (n =178)
Analyzed
(n =1011)
Excluded (n =28)
-Age <18 years (n =12)
-FU duration <1 year (n =8)
-Presence of malignancy (n =3)
-Advanced liver disease (n =5)
Excluded (n =59)
-Age <18 years (n =26)
-FU duration <1 year (n =20)
-Presence of malignancy (n =3)
-Advanced liver disease (n =10)
Figure 1 | Flow diagram of patient progress and outcomes. From January 2000 to September 2010, we enrolled 120 patients with
biopsy-proven Heno¨ch-Scho¨nlein purpura nephritis (HSPN) and 1070 patients with immunoglobulin A nephropathy (IgAN) from four
medical centers in Korea. After 1:2 propensity score (PS) matching, 89 patients with HSPN and 178 patients with IgAN were ultimately
analyzed. Cr, creatinine; ESRD, end-stage renal disease; FU, follow-up.
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and in 11 patients (1.1%) with IgAN (P¼ 0.310). In patients
with IgAN, the rate of decline in eGFR was greater than in
patients with HSPN (3.81 vs. 3.03 ml/min per 1.73 m2/year,
P¼ 0.023; Figure 3a). The remission rate was significantly
higher in patients with HSPN than in patients with IgAN
(28.3% vs. 13.8%, P¼ 0.002; Table 2). In a multivariate Cox
proportional analysis adjusted for age, gender, mean arterial
pressure, serum creatinine, eGFR, serum albumin, total
cholesterol concentrations, 24-h urinary protein excretion,
steroid use, and pathologic findings such as glomerulosclerosis
and interstitial fibrosis, the risk of reaching the composite
outcome was significantly lower in patients with HSPN than in
patients with IgAN (hazard ratio (HR), 0.67; 95% confidence
interval (CI), 0.43–0.96; P¼ 0.044; Table 3). This risk
Table 1 | Patient characteristics by biopsy-proven pathologic diagnosis at baseline (before and after propensity score 1:2
matching)
Unmatched cohort Matched cohort
Variables HSPN (n=92) IgAN (n=1011) P-value HSPN (n=89) IgAN (n=178) P-value
Age (years) 33.2±15.9 37.7±13.0 0.010 33.8±15.9 34.7±12.6 0.644
Male gender, n (%) 47 (51.1) 474 (46.9) 0.447 45 (50.6) 84 (47.2) 0.606
Hypertension, n (%) 23 (25.0) 134 (13.3) 0.004 22 (24.7) 52 (29.2) 0.471
DM, n (%) 3 (3.3) 15 (1.5) 0.184 3 (3.4) 4 (2.2) 0.689
Hepatitis B surface antigen positivity, n (%) 2 (2.2) 31 (3.1) 0.306 2 (2.2) 4 (2.2) 1.000
SBP (mmHg) 119±14.5 124±34.4 0.220 120±14.6 121±13.0 0.543
DBP (mmHg) 76.9±9.1 77.0±9.1 0.927 77.0±9.0 76.8±9.9 0.864
MAP (mmHg) 91.1±9.6 92.6±14.3 0.313 91.3±9.5 91.5±10.2 0.868
Gross hematuria, n (%) 17 (18.5) 251 (24.8) 0.237 16 (18.0) 37 (20.8) 0.461
Extrarenal manifestations, n (%)
Purpura 92 (100) — — 89 (100) — —
GI symptoms 44 (47.8) — — 42 (47.2) — —
Presence of arthritis 17 (18.5) — — 17 (19.1) — —
Pathology reports, n (%)
Glomerulosclerosis 0.566 0.511
None 69 (75.0) 765 (75.6) 66 (74.1) 122 (68.6)
Segmental 11 (12.0) 131 (13.0) 11 (12.4) 28 (15.7)
Global 12 (13.0) 115 (11.4) 12 (13.5) 28 (15.7)
Interstitial fibrosis 0.041 0.482
Mild (0–25%) 17 (18.5) 231 (22.8) 15 (16.8) 27 (15.2)
Moderate (26–50%) 12 (13.0) 211 (20.9) 12 (13.5) 27 (15.2)
Severe (450%) 9 (9.8) 127 (12.6) 7 (7.9) 9 (5.1)
Laboratory measurements
SCr (mg/dl) 1.0±0.2 1.1±0.6 0.128 1.1±0.4 1.0±0.3 0.817
eGFR (ml/min per 1.73m2) 90.2±26.5 86.5±39.9 0.411 89.5±25.9 90.5±28.0 0.402
eGFRo30 0 (0.0%) 13 (1.3%) 0.164 0 (0.0%) 0 (0.0%) 1.000
30peGFRo60 7 (7.6%) 132 (13.1%) 7 (7.9%) 14 (7.9%)
eGFRX60 85 (92.4%) 866 (85.7%) 82 (92.1%) 164 (92.1%)
Serum albumin (g/dl) 3.9±0.6 4.0±0.7 0.228 3.9±0.6 3.9±0.8 0.805
Total cholesterol (mg/dl) 183±57.4 190±51.2 0.315 183±57.5 197±63.5 0.151
Serum IgA level (g/l) 323±109 309.4±93.7 0.567 325.6±108.5 313.4±169.9 0.608
C3 (mg/dl) 106±22.1 101±21.5 0.457 107±25.8 106±23.9 0.821
C4 (mg/dl) 24.1±8.0 25.3±6.8 0.812 24.4±7.9 26.0±9.7 0.317
UPCR (mg/mg)a 1.01 (0.02–12.8) 1.05 (0.02–18.2) 0.231 1.01 (0.02–12.8) 1.14 (0.02–10.8) 0.242
24-h protein excretiona (g/day) 1.15 (0.35–15.7) 1.32 (0.11–16.1) 0.130 1.14 (0.35–13.9) 1.20 (0.11–11.8) 0.445
CRP (mg/l)a 2.65 (1.0–115.0) 1.49 (1.0–56.8) 0.014 2.49 (1.0–95.0) 1.73 (1.0–26.5) 0.073
FU duration (month) 63.3±60.4 59.2±27.4 0.325 62.5±60.2 60.7±31.2 0.543
Treatments, n (%)
RAS blockades 69 (75.0) 778 (76.9) 0.698 66 (74.2) 133 (74.7) 0.722
Steroid 37 (40.2) 144 (14.2) 0.001 34 (38.2) 59 (33.1) 0.417
Steroid+cyclosporin 0 (0.0) 22 (2.2) — 0 (0.0) 5 (2.8) —
Steroid+cyclophosphamide 7 (7.6) 52 (5.1) 0.103 7 (7.9) 11 (6.2) 0.672
Duration between biopsy procedure and
steroid start (month)
9.6±14.8 25.3±17.8 0.007 9.7±14.6 11.3±16.0 0.573
Duration of steroid (day)a 237 (154–716) 281 (150–978) 0.101 234 (154–716) 256 (150–931) 0.473
Abbreviations: CRP, C-reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FU, follow-up; GI, gastrointestinal;
HSPN, Heno¨ch-Scho¨nlein purpura nephritis; IgAN, immunoglobulin A nephropathy; MAP, mean arterial pressure; RAS, renin–angiotensin system; SBP, systolic blood pressure;
SCr, serum creatinine; UPCR, urinary protein-to-creatinine ratio.
Data are n (%), mean±s.d.
aData are expressed as median (range).
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reduction was largely attributed to the reduction in the
occurrence of ESRD in patients with HSPN compared with
patients with IgAN (HR, 0.61; 95% CI, 0.34–0.96; P¼ 0.034;
Table 4). However, there was no difference in the renal
outcome of D-SCr between the two groups (HR, 0.63; 95%
CI, 0.36–1.40; P¼ 0.180; Table 4).
Patient outcomes for the matched cohort
In the matched cohort, 16 patients (18.0%) with HSPN
reached a composite outcome compared with 38 patients
(21.3%) with IgAN (P¼ 0.309; Figure 2d). There were no
significant differences in the individual renal outcome of
D-SCr (15.7% vs. 18.0%, P¼ 0.848; Figure 2e) or ESRD
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Figure 2 |Clinical outcomes between Heno¨ch-Scho¨nlein purpura nephritis (HSPN) and immunoglobulin A nephropathy (IgAN).
(a–c) Kaplan–Meier plots for outcomes in the unmatched and (d–f) the matched cohort. In the unmatched cohort, the event-free survival for
composite outcome (P¼ 0.047) (a) and end-stage renal disease (ESRD; P¼ 0.034) (c) was significantly lower in patients with HSPN than in
patients with IgAN. There was no significant difference in the doubling of serum creatinine from the baseline between the two groups
(b) (P¼ 0.075). In the matched cohort, the event-free survival for composite outcome (d), doubling of the baseline serum creatinine (e), and
ESRD (f) did not differ between the two groups.
Table 2 | Renal outcomes before and after propensity score 1:2 matching
Unmatched cohort Matched cohort
Renal outcomes, n (%) HSPN (n=92) IgAN (n=1011) P-value HSPN (n=89) IgAN (n=178) P-value
Remission 26 (28.3) 140 (13.8) 0.002 25 (28.1) 49 (27.5) 0.803
Persistent proteinuria and/or hematuria# 44 (47.8) 424 (41.9) 0.387 43 (48.3) 82 (46.1) 0.617
Mod or severe renal insufficiency$ 9 (9.8) 225 (22.3) 0.001 8 (9.0) 23 (12.9) 0.209
SCr doubling 16 (17.4) 249 (24.6) 0.075 14 (15.7) 32 (18.0) 0.848
ESRD 13 (14.1) 222 (22.0) 0.034 13 (14.6) 24 (13.5) 0.632
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HSPN, Heno¨ch-Scho¨nlein purpura nephritis; IgAN, immunoglobulin A nephropathy;
SCr, serum creatinine.
Data are n (%), mean±s.d.
Definitions: #Proteinuria and/or hematuria: proteinuria and/or hematuria without renal insufficiency, $Renal insufficiency: eGFRo60ml/min per 1.73m2, $Moderate renal
functional impairment: eGFR between 30 and 60ml/min per 1.73m2, $Severe renal failure: eGFRp30ml/min per 1.73m2.
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(14.6% vs. 13.5%, P¼ 0.632; Figure 2f, Table 2). In addition, the
rate of decline in eGFR (2.46 vs. 2.94 ml/min per 1.73 m2/
year, P¼ 0.884, Figure 3b) and the remission rate (Table 2)
were also similar in both groups. In a multivariate Cox
analysis adjusted for clinical factors, steroid use, and
pathologic findings, the risk of the composite outcome was
comparable in patients with HSPN and patients with IgAN
(HR, 0.78; 95% CI, 0.47–1.36; P¼ 0.166; Table 3). In
addition, the risk of reaching D-SCr (HR, 0.74; 95% CI,
0.49–1.52; P¼ 0.132) and developing ESRD (HR, 0.77; 95%
CI, 0.59–1.53; P¼ 0.181) did not differ between the two
groups (Table 4).
DISCUSSION
It has been suggested that HSPN and IgAN represent a
spectrum of clinical presentations of the same disease.2–6 As
in patients with IgAN, the lack of terminal b1-galactosyl
residues in the hinge region of IgA1 is observed in patients
with HSPN and such aberrantly glycosylated IgA1 levels are
elevated in the patients’ serum of IgAN and HSPN.5,12–14 In
addition, IgA-containing complexes were demonstrated in
both IgAN and HSPN and no major biologic differences
concerning IgA-containing complexes were found between
the two entities except for the higher IgG content and bigger
size in patients with HSPN.5 Mesangial C3 deposits are also
commonly seen in IgAN and HSPN15 and complement
activation particularly via the alternative or the lectin
pathway is known to be involved in the pathogenesis.16,17
Finally, a recent study by Kiryluk et al. showed that galactose-
deficient IgA1 levels were highly inherited, 76% and 64% in
pediatric patients with IgAN and HSPN, respectively.18 All
these findings together suggest that IgAN and HSPN share
common pathogenic mechanisms. Despite their similar
pathophysiology, it is interesting that clinical manifestations
of IgAN and HSPN at presentation are different. This led us
to question ‘Are clinical outcomes of IgAN and HSPN
different?’ In this study, we tried to provide a clue to this
problem by directly comparing these two different forms of
the same disease.
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Figure 3 |Changes in estimated glomerular filtration rate
(eGFR) in Heno¨ch-Scho¨nlein purpura nephritis (HSPN) and
immunoglobulin A nephropathy (IgAN) patients. (a) In the
unmatched cohort, the rate of decline in eGFR in IgAN was greater
than in HSPN (P¼ 0.023). (b) In the matched cohort, there was no
difference in the rate of decline in eGFR between the two groups
(P¼ 0.884).
Table 3 |Multivariate Cox proportional analyses for composite outcomes*
Unmatched cohort Matched cohort
HR (95% CI) P-value HR (95% CI) P-value
Age (years) 1.01 (0.98–1.05) 0.385 1.00 (0.97–1.04) 0.888
Male (vs. female) 0.73 (0.20–2.66) 0.629 0.53 (0.22–1.26) 0.531
HSPN (vs. IgAN) 0.67 (0.43–0.96) 0.044 0.78 (0.47–1.36) 0.166
MAP (mmHg) 1.03 (0.98–1.08) 0.198 0.98 (0.94–1.02) 0.324
SCr (mg/dl) 2.34 (1.03–9.68) 0.029 11.3 (3.44–59.96) 0.001
eGFR (ml/min per 1.73m2) 0.98 (0.94–1.03) 0.484 1.00 (0.97–1.03) 0.971
Baseline 24 h proteinuria (per 1 g/day) 1.10 (1.01–1.36) 0.016 3.22 (1.16–8.93) 0.024
Serum albumin (g/dl) 0.57 (0.21–0.56) 0.272 0.32 (0.16–0.66) 0.002
Total cholesterol (mg/dl) 0.99 (0.97–0.99) 0.036 0.99 (0.99–1.00) 0.162
Pathologic findings
Glomerulosclerosis (vs. none) 1.74 (0.41–7.83) 0.481 0.95 (0.16–5.34) 0.950
Interstitial fibrosis (vs. none) 2.23 (0.59–8.14) 0.232 1.10 (0.22–5.36) 0.911
Steroid therapy (vs. no use) 1.09 (0.94–1.26) 0.265 1.02 (0.36–2.89) 0.967
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; HSPN, Heno¨ch-Scho¨nlein purpura nephritis; IgAN, immunoglobulin A
nephropathy; MAP, mean arterial pressure; SCr, serum creatinine.
*Adjusted for age, gender, MAP, serum creatinine, eGFR, serum albumin, total cholesterol concentrations, 24-h urinary protein excretion, pathologic findings, and the use of
steroid treatment.
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Several studies have shown that renal survival rates in
adult HSPN patients are up to 80% at 10 years.10,11,19
Considering that 15–20% of adult patients with IgAN reach
ESRD within 10 years from the onset of disease, and up to
25–34% within 20 years,5,7 both IgAN and HSPN appear to
have a similar prognosis. However, these results should be
interpreted with caution because prior studies clearly showed
that many patients with HSPN have moderate-to-nephrotic
range proteinuria, renal insufficiency, or both at the onset of
disease,9,10 whereas most patients with IgAN initially have
asymptomatic urinary abnormalities with normal renal
function and minimal-to-moderate proteinuria. Further-
more, patients with HSPN are more frequently treated with
steroids or other immunosuppressive drugs compared with
patients with IgAN. These findings make it difficult to
interpret the results of prior studies because initial renal
function and immunosuppressive drugs may affect clinical
outcomes. To overcome this limitation, we used PS matching
and controlled for any inequalities in baseline conditions.
With this rigorous adjustment, we found that the long-term
prognoses of these two clinical entities of the same disease
were comparable.
In line with previous studies,11,20,21 considerably more
patients with HSPN were treated with steroids than patients
with IgAN in the unmatched cohort of our study (40.2% vs.
14.2%, P¼ 0.001). This can be explained by the fact that
initial features of vasculitis are more common in patients
with HSPN. In fact, patients with HSPN in our study had
more extrarenal manifestations at the onset of HSPN than
patients with IgAN. Vasculitic feature in patients with HSPN
is more evidenced by elevated C-reactive protein levels. It is
possible that many physicians have a strong impression that
HSPN is a systemic vasculitis, and the symptoms and signs
are relatively severe in patients with HSPN. These factors may
result in early administration of immunosuppressive drugs to
these patients. In contrast, IgAN progresses slowly, a rapid
decline in kidney function is rare, and there are no extrarenal
manifestations. Therefore, steroids are generally indicated
only if there is evidence of increasing proteinuria or
worsening renal function despite conventional treatment,
such as renin–angiotensin system blockers. In support of this
notion, we observed that the time interval between the onset
of disease and the initiation of steroids was significantly
longer in patients with IgAN than in patients with HSPN
(25.3 vs. 9.6 months; P¼ 0.007, Table 1).
In this regard, early administration of steroids may lead to
better outcomes in patients with HSPN than in patients with
IgAN. In fact, the complete remission rate was significantly
higher in patients with HSPN than in patients with IgAN
(28.3% vs. 13.8%, P¼ 0.002) in the unmatched cohort of our
study. A similar trend was observed in the matched cohort, but
it did not reach statistical significance. Whether this finding
suggests that responsiveness to steroids is more favorable in
patients with HSPN is uncertain. Presumably, HSPN present-
ing with acute onset of the clinical features of vasculitis may
suggest that an inflammatory process is active. Therefore, we
can speculate that administration of steroids in the active
inflammatory stage is effective. In contrast, patients with IgAN
who undergo late initiation of steroids may have chronic
subclinical inflammatory injury. During the period of the
delay, it is possible that chronic lesions, such as glomerulo-
sclerosis, tubular atrophy, or interstitial fibrosis, which are
considered irreversible, may develop and result in attenuation
of the efficacy of steroids. We were unable to demonstrate
chronic injury in patients with IgAN because a second biopsy
was not feasible. However, in these patients, eGFR decreased
from 83.4 to 58.5 ml/min per 1.73 m2 and UPCR increased
from 1.1 to 2.2 mg/mg when steroids were initiated (data not
shown), suggesting that chronic inflammatory injury was
ongoing. However, the role of immunosuppressive drugs is not
clearly defined for either HSPN or IgAN. Although steroids
may be effective in some patients with IgAN who have
proteinuria 41.0 g/day and GFR450 ml/min,22 to date, there
is no convincing evidence from the literature that therapy with
immunosuppressive drugs, such as steroids, has a beneficial
effect in patients with HSPN.11,23–26 In addition, our study
showed that the use of immunosuppressive drugs was not
associated with a decreased risk of renal outcomes in the
multivariate analysis. Therefore, it is difficult to draw a
meaningful conclusion from our observational study about
whether early initiation of steroids is beneficial.
In the unmatched cohort, unlike in previous studies
showing that renal insufficiency or nephrotic range protei-
nuria was relatively common in adult patients with HSPN,
initial renal function and the level of proteinuria were similar
between the two groups in our study. It is possible that
kidney biopsy was performed earlier because there was a
strong suspicion of HSPN due to other extrarenal manifesta-
tions even if patients had minimal-to-moderate proteinuria.
Relevant to this assumption is our pathologic findings at
presentation that interstitial fibrosis was less common in
patients with HSPN (Table 1). This finding can also explain
the more rapid decline in eGFR and the higher risk of the
primary outcome in patients with IgAN in the unmatched
cohort (Figure 3a).
Our study had several limitations. First, this was an
observational study in which the effect of confounding by
indication could not be fully excluded. Some important
baseline covariates were not distributed equally. To address
Table 4 |Multivariate Cox proportional analyses for SCr
doubling and ESRDa
Unmatched cohort Matched cohort
HR (95% CI) P-value HR (95% CI) P-value
SCr  2 0.63 (0.36–1.40) 0.180 0.74 (0.49–1.52) 0.132
ESRD 0.61 (0.34–0.96) 0.034 0.77 (0.59–1.53) 0.181
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; HR, hazard
ratio; SCr, serum creatinine.
SCr  2: a doubling of the baseline serum creatinine concentration.
aAdjusted for age, gender, mean arterial pressure, Scr, estimated glomerular
filtration rate, serum albumin, total cholesterol concentrations, 24-h urinary protein
excretion, pathologic findings, and the use of steroid treatment.
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this, PS matching was used to minimize differences in
baseline characteristics. Despite these efforts, differences in
unmeasured characteristics could have led to biased results.
Second, because there are no preset indications for treating
HSPN and IgAN, treatment differed depending on indivi-
dual physician preferences and steroid protocols were not
uniform. Therefore, it is difficult to evaluate the effects
of immunosuppressive drugs on clinical outcomes in this
study. However, as mentioned earlier, the role of immuno-
suppressive drugs is not yet clearly defined for HSPN and
IgAN. Third, although HSPN and IgAN are considered
different manifestations of a single disease, these two clinical
entities have different classification methods: the Interna-
tional Study of Kidney Disease in Children classification
(ISKDC) classification for HSPN27 and Haas classification
for IgAN.28 Therefore, pathologic findings were not adjusted
in the multivariate model. However, we added variables,
such as interstitial fibrosis and glomerulosclerosis, into the
model that are known to be important factors associated
with adverse outcomes. In fact, the ISKDC classification is
based on the presence of crescents. However, there is concern
that crescents per se are not signs of irreversible damage in
patients with HSPN, thus may not be predictive of long-term
outcome.19 A new classification that can integrate both
HSPN and IgAN may be helpful to compare the clinical
outcomes. Fourth, there was no difference in the composite
outcome between the two groups until 90 months. This is
probably because composite outcome was counted only
when a doubling of the serum creatinine or ESRD occurred.
It is well known that serum creatinine level remains stable
when GFR decreases to 60 ml/min per 1.73 m2 due to an
increase in proximal tubular creatinine secretion. In fact,
baseline mean eGFR in patients with IgAN was 86.5 ml/min
per 1.73 m2, therefore there might be a delay until serum
creatinine level reached to a doubling of the baseline value.
Interestingly, Figure 3a clearly showed that rate of decline in
eGFR was greater in patients with IgAN than in patients with
HSPN before 90 months. This finding suggests that, in the
unmatched cohort, progression of kidney disease may
actually be faster in patients with IgAN than in patients
with HSPN. Finally, the follow-up duration was relatively
shorter than previous studies.10,11 Given that IgAN pro-
gresses very slowly, a longer period of observation is required
to validate our findings.
In conclusion, we demonstrated that, in the unmatched
cohort, clinical outcomes were more unfavorable in
patients with IgAN than in patients with HSPN, but this
difference disappeared after the unequal baseline covariates
were controlled by PS matching. Unfortunately, randomized,
controlled studies that compare HSPN with IgAN appear to
be unfeasible because these two forms of the same
disease have different clinical features at presentation;
therefore, it is difficult to balance baseline conditions. In
this regard, our novel findings may provide a better
understanding of the nature of IgAN and HSPN that have
a similar pathogenesis.
MATERIALS AND METHODS
Patients
The study sample comprised 120 patients with HSPN and 1070
patients with IgAN who were recruited from four medical centers in
Korea between January 2000 and September 2010. All patients
underwent a renal biopsy. A diagnosis of HSPN was made when
hematuria, proteinuria, or renal failure was associated with a
palpable purpuric eruption or abdominal or joint pains, and
predominant mesangial IgA immune deposits were confirmed by a
renal biopsy.11 In addition, all patients with IgAN had definite
pathologic findings with predominant mesangial deposition of IgA
with at least 1þ on immunofluorescent staining and electron-dense
deposits within the mesangium detected by electron microscopy.
Renal biopsy was generally recommended when patients had
persistent hematuria and proteinuria at least X500 mg/day. In
addition, when patients had an episode of dark-colored gross
hematuria following upper respiratory infection, which is a typical
feature of the onset of IgAN, they were usually recommended for
renal biopsy. Exclusion criteria were as follows: ageo18 years of age
(n¼ 38), lost to follow-up within 1 year (n¼ 28), malignancy
(n¼ 6), and chronic advanced liver disease (n¼ 15; Figure 1).
Therefore, 92 patients with HSPN and 1011 patients with IgAN were
included in the analysis.
Data collection
Using medical records, demographic and clinical data were reviewed
retrospectively for age, gender, medical history, medications, follow-
up duration, and time to D-SCr and ESRD. Laboratory data
included serum creatinine, albumin, total cholesterol concentra-
tions, serum IgA, complement levels, hepatitis B antigen positivity,
and UPCR. We also collected data for 24-h urinary protein excretion
levels, which were available for 91 patients (98.9%) with HSPN and
829 patients (82.0%) with IgAN. Data for serum C-reactive protein
levels were also obtained from medical records, which were available
for 74 patients (80.4%) with HSPN and 749 patients (74.1%) with
IgAN. The eGFR was calculated using the four-variable Modification
of Diet in Renal Disease study equation.29
Renal pathology data included information on the number of
glomeruli and the presence of global or segmental sclerosis, foot
process effacement, mesangial hypercellularity, endocapillary pro-
liferation, tubular atrophy, and interstitial fibrosis. HSPN was
graded by the ISKDC,27 and IgAN was classified by the Haas
system.28
Treatment
Normotensive patients who excreted o0.5 mg/mg of UPCR were
not typically treated with renin–angiotensin system blockers.
Renin–angiotensin system blockers were initiated if there was
evidence of hypertension or UPCRX0.5 mg/mg.30,31 Steroid treat-
ment was initiated when patients had persistent heavy proteinuria of
43.0 g/day and were unresponsive to renin–angiotensin system
blockers and had evidence of severe active inflammation with
deterioration of kidney function. In particular, in patients with
IgAN, the most commonly used regimen was intravenous admin-
istration of 1.0 g of methylprednisolone for three consecutive days at
the beginning of steroid treatment and again 2 and 4 months later
followed by 0.5 mg/kg of oral prednisolone given on alternate days
for 6 months as suggested by Pozzi et al.32 Other immunosuppres-
sive drugs, such as cyclosporine or cyclophosphamide, were added
in cases of incomplete response or steroid intolerance.
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In patients with HSPN, steroids were often administered when
systemic manifestations of vasculitis were evident even if they did
not have nephrotic range proteinuria.
Study outcomes
Patients were followed at dialysis therapy. If patients were lost to
follow-up or died during the study, they were followed until the last
recorded visit. The primary end point was the composite of D-SCr,
the onset of ESRD, or death. The secondary end point included the
individual renal outcomes of D-SCr, ESRD, and the rate of decline
in eGFR. D-SCr was defined as a sustained, greater than twofold
increase in serum creatinine levels for at least three consecutive
measurements.
In addition, renal outcomes were classified as remission (no renal
failure, proteinuria, or hematuria), persistent proteinuria and/or
hematuria without renal insufficiency, moderate or severe renal
insufficiency, and ESRD.11 We defined persistent proteinuria as
UPCRX0.2 mg/mg, hematuria asX3 red blood cells per high power
field, renal insufficiency as eGFRo60 ml/min per 1.73 m2, moderate
renal functional impairment as eGFR between 30 and 60 ml/min per
1.73 m2, and severe renal failure as eGFRp30 ml/min per 1.73 m2.
Statistical analyses
This study was a matched cohort study using HSPN and IgAN
patients to analyze the effect of several potential confounders. The
patients were matched 1:2 by PS using the greedy matching
algorithm (8 to 1 digit match).33 Once the IgAN patients were
matched, the HSPN patients are not reconsidered. The algorithm
makes ‘best’ matches first and ‘next-best’ matches next in a
hierarchical sequence until no more matches can be made. Best
matches are those with the highest digit match on PS. First,
IgAN patients were matched to HSPN patients on 8 digits of
the PS. For those that did not match, IgAN patients were then
matched to HSPN patients on 7 digits of the PS. The algorithm
proceeds sequentially to the lowest digit match on PS (1 digit). We
derived the PS from a multi-logit regression model with all of the
following variables: age, gender, presence of diabetes, hypertension
or both, serum creatinine, eGFR, serum albumin, total cholesterol
concentrations, 24-h urinary protein excretion levels, pathologic
findings, and treatment modalities. After all PS matches
were performed, we assessed the balance in baseline covariates
between the two groups using the Wilcoxon signed rank test for
continuous variables and the McNemar’s test for categorical
variables. PS matching was conducted using SAS, version 9.1
(SAS Institute, Cary, NC).
For continuous variables, results were expressed as mean±s.d. as
indicated. Comparisons were based on the w2-test for categorical
variables, and t-test or Mann–Whitney test for continuous variables.
The end-point curves from the day of renal biopsy were computed
using Kaplan–Meier estimates. A Cox model was fit to evaluate the
influence of the following variables on the occurrence of severe renal
failure: age, gender, serum creatinine, albumin, total cholesterol
concentrations, eGFR, and 24-h urinary protein excretion levels. The
results were presented as a HR and 95% CI. Violation of the
proportional hazards assumption was tested by conducting a time-
dependent Cox regression analysis in which the two diseases were
considered a time-dependent variable. We found that the interaction
between time and the two diseases was not statistically significant,
thus proportional assumptions were not violated. A linear mixed
model was also applied to compare the rate of decline in eGFR
between the two groups. All tests were two-sided, and Po0.05 was
considered significant. Statistical analyses were performed with SPSS
18.0 (SPSS, Chicago, IL).
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